Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Priority to MX9700775ApriorityCriticalpatent/MX9700775A/en
Publication of MXPA97000775ApublicationCriticalpatent/MXPA97000775A/en
Publication of MX9700775ApublicationCriticalpatent/MX9700775A/en
The present invention refers to employment of tetrahydroisoquinoline derivatives of general formula (See Formula) wherein A is aryl; R1 is hydrogen, hydroxyl, lower alkyl, lower alkoxyl, R-CO- or R-CO-, wherein R is lower alkyl, R2 is hydrogen, lower alkyl, o cycloalkyl, R3-R7 are hydrogen, lower alkyl, lower alkoxyl, hydroxyl, or R3 and R4 jointly taken are -(CH2)n- or R6 and R7 jointly taken are -OCH20- and n is 3 or 4, as well as pharmaceutically acceptable salts, to manufacture medicaments to control or to treat diseases representing therapeutic indications for NMDA receptors sub-type specific blocking agents.
Use of idazoxan and its derivatives for the preparation of a medicinal product intended for the treatment of parkinson's disease and its development
Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases.